Clinical Trial Update: A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC [Phase 4]

View source ↗

Summary

Phase 4 study evaluating adults with chronic inflammatory demyelinating polyneuropathy transitioning from intravenous immunoglobulin to subcutaneous efgartigimo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Phase 4 | Status: COMPLETED